The Janus-activated kinase 1 (JAK1) and JAK2 inhibitor ruxolitinib is effective in decreasing symptomatic splenomegaly and myelofibrosis (MF)-related symptoms. However, allogeneic hematopoietic cell transplantation (HCT) remains the only curative option. We evaluated the impact of ruxolitinib on the outcome after HCT. A cohort of 14 patients (median age 58 years) received a subsequent graft from related (n ¼ 3) and unrelated (n ¼ 11) donors after a median exposure of 6.5 months to ruxolitinib. At HCT, MF risk for survival according to the International Prognostic Scoring System was intermediate-2 or high risk in 86% of patients. Under ruxolitinib, MF-related symptoms were ameliorated in 10 (71.4%) patients and the palpable spleen reduced by a median of 41% in 7 (64%) of 11 patients with splenomegaly. Engraftment occurred in 13 (93%) patients. Acute GvHD grade-III occurred in 2 (14%) patients. Median follow-up was 9 months. Survival, EFS and treatment-related mortality were 78.6, 64 and 7%, respectively. Through the anti-JAK-mediated reduction in both cytokines and splenomegaly as well as improvement in performance status, ruxolitinib might improve outcome after allogeneic HCT in patients with MF. The downregulation of inflammatory cytokines might have a beneficial impact on graft failure and acute GvHD.
INTRODUCTION
Myelofibrosis (MF), including primary MF, post polycythemia vera MF and post essential thrombocythemia MF, is a rare hematological disease affecting mainly elderly patients, characterized by a variable clinical course, and often associated with constitutional symptoms and splenomegaly. 1 Identifying optimal treatment strategies for patients with MF is challenging as options range from ''watch and wait'' to allogeneic hematopoietic cell transplantation (HCT). An individualized and risk-adapted approach is usually required.
With the approval of ruxolitinib, a Janus-activated kinase 1 (JAK1) and JAK2 inhibitor which inhibits dysregulated JAK-STAT (signal transducer and activator of transcription factor) signaling in both JAK2V617F-positive and -negative diseases, the treatment landscape for patients with MF has changed. 2, 3 Ruxolitinib is effective in decreasing splenomegaly, MF-related symptoms and causes improvement in quality of life. Some data also suggest that treatment with ruxolitinib might be associated with a survival benefit. 2 However at this time, ruxolitinib cannot be considered to be curative. Although a large proportion of patients is beyond the transplant age group, allogeneic HCT remains the only curative option for MF.
Despite notable advances that have improved outcome after allogeneic HCT such as high-resolution typing of unrelated donors and the introduction of reduced intensity conditioning (RIC), controversies regarding its application in MF patients and concerns regarding allogeneic HCT-related morbidity and mortality remain. 4 In a rare and heterogeneous disease affecting mainly elderly patients, challenges in the transplant setting are patient selection, timing of allogeneic HCT and the type of conditioning regimen. Though a variety of disease-and patient-related factors have been identified that might support decision-making, the complex issue of allocating patients to allogeneic HCT is often subjective and based on the physician's opinion. With the availability of ruxolitinib, the risk/benefit considerations, at least for some patients, might change. Thus, incorporating ruxolitinib in treatment strategies might change the positioning of transplantation and provide a chance to improve outcome in patients with MF. In this analysis, we present data on 14 consecutive patients with MF who received an allogeneic HCT following treatment with ruxolitinib at the University of Leipzig, Leipzig, Germany. Response to ruxolitinib preceding allogeneic HCT, decision making and risk stratification for transplantation as well as outcome after allogeneic HCT with focus on disease-and patient-related features as prognostic determinants of outcome are discussed. Subsequently, potential candidates for allogeneic HCT were identified if all of the following patient-related criteria were met: ECOG (Eastern Cooperative Oncology Group) PSp2, ageo70 years, no significant 1 comorbidities, and a suitable related or unrelated donor available. Accordingly, 14/47 (29.8%) patients with primary MF (n ¼ 11), post polycythemia vera MF (n ¼ 2) and post essential thrombocythemia MF (n ¼ 1) received an allogeneic HCT at a median age of 58 (range 33-68) years. Patient characteristics are shown in Table 1 . The spleen was palpable in 11 (78.6%) patients with a median of 11.5 (range 7-25) cm below the costal margin. Constitutional symptoms according to the IPSS (weight loss, unexplained fever, and night sweats) were present in 11 (79%) patients (Table 2) . Additionally, the frequently present MF-related symptoms of fatigue, bone pain and pruritus were present in 11 (79%), 5 (36) and 4 (29) patients, respectively. Overall, the above mentioned six MF-related symptoms were present in 13 (83%) patients with a median of 3 (range 1-4) symptoms.
PATIENTS AND METHODS

Between
Response to ruxolitinib was assessed at each visit by measurement of the spleen below the costal margin and evaluation of the disease burden. Besides the judgment of the clinician, the self-assessment of patients of the severity of the six symptoms (weight loss, unexplained fever, night sweats, fatigue, bone pain and pruritus) on a scale from 0 (not present) to 4 (very severe) was also used. A meaningful amelioration of MF-related symptoms under treatment was considered to be present if a reduction of at least 50% from baseline score was reached.
To allocate a potential patient to allogeneic HCT, survival risk stratification of MF using the dynamic IPSS (DIPSS), DIPSS plus and the Lille scoring systems was applied. [6] [7] [8] The published refined cytogenetic-risk categorization for overall and leukemia-free survival in MF was used. 9 Before ruxolitinib, analysis of the prognostic factors relevant for survival revealed that 9 (64%) patients were high risk and intermediate-2 risk,, according to IPPS ( /kg recipient body weight CD34 þ cells. Measurement of JAK2 p.V617F allele burden from peripheral blood and BM samples before ruxolitinib, before allogeneic HCT as well as 28 days following transplantation was done as previously described. 10 The level of JAK2 p.V617F-mutated allele was normalized to that of the HCK gene and expressed as JAK2 p.V617F-mutated alleles per HCK allele to enable quantification. Overall, 9 (64.3%) patients had JAK2V617F-positive disease with a median allele burden of 47.5% JAK2V617F/HCK before ruxolitinib (range 1-100%) ( Figure 1) .
Assessment of donor chimerism in both unsorted and CD3 þ peripheral and BM cells on day 28 after allogeneic HCT was performed by PCR-based amplification of STR sequences. 11 Before allogeneic HCT, the approval of the procedure and subsequent analysis of the data was obtained from all patients and a second informed consent was signed.
RESULTS
Response to ruxolitinib before allogeneic HCT Ruxolitinib was initiated in all patients because of symptomatic splenomegaly and/or severe MF-related symptoms. The starting dose of ruxolitinib was based on platelet count. Six patients with platelets 4200 000/mm 3 received 20 mg orally twice daily (BID), seven patients with platelets 100 000-200 000/mm 3 were treated with 15 mg BID and one patient with platelets o100 000/mm 3 received a total daily dose of 15 mg (5 mg in the morning and 10 mg in the evening). Treatment was generally well tolerated. No patient was discontinued because of adverse events. Modifications of the ruxolitinib dose were done if thrombocytopenia or neutropenia developed according to the guidelines published. 2, 3 Between weeks 4 and 12, the initial dose had to be adjusted in 8 (57%) patients because of thrombocytopenia in seven and neutropenia in one. On the whole, ruxolitinib was given for a median of 6.5 (range 2-12) months. MF-related symptoms improved rapidly with a median reduction of the score of the six assessed MF-related symptoms of 52.5% (range 0-100%) occurring between week 4 and week 8 of therapy. An amelioration of MF-related symptoms as defined under Patients and methods occurred in 11 (78.6%) patients and was durable till allogeneic HCT in 10 (71.4%) patients. In one patient (no. 12), ruxolitinib had to be withdrawn after 10 weeks and induction chemotherapy (IC) given because of rapidly progressive leucocytosis.
Under treatment, a median reduction in the palpable spleen below the costal margin of 41% (range 20-100%) occurred in 9 (82%) of the 11 patients with splenomegaly before ruxolitinib. The maximal response was documented after a median of 12 weeks and was durable till allogeneic HCT in seven patients. In one newly diagnosed patient with intermediate-1 risk MF (no. 5), the splenic response occurred at week 8, lasted for 4 months, and was lost at the time of leukemic transformation (LT). Patient no. 12 had a 20% reduction in palpable spleen documented at week 8, but ruxolitinib had to be stopped 2 weeks later as previously mentioned. Of the two patients with no splenic response, an LT was diagnosed in patient no. 2 8 weeks after commencing ruxolitiinib. Patient no. 11 had a reduction of 33% of MF-related symptoms but no splenic response. This patient received an allogeneic HCT 5.5 months later (Table 3) .
Besides the two patients with LT, new adverse prognostic factors for survival were documented in three patients while receiving ruxolitinib before allogeneic HCT. Patient no. 4 Ruxolitinib and SCT N Jaekel et al developed a transfusion-dependent anemia 8 months after commencing ruxolitinib. Patient no. 12 had 5% blasts in the peripheral blood. In patient no. 3, a progressive thrombocytopenia not responsive to ruxolitinib dose reduction emerged 8 months after initiating therapy (Table 2) . Preceding allogeneic HCT, two patients had a LT, 6 patients were high risk and 5 patients intermediate-2 risk according to the IPSS. The one patient (no. 9) with intermediate-1 risk was transplanted because of young age.
Irrespective of clinical response to ruxolitinib, the allele burden in patients with JAK2V617F-positive disease remained unchanged or increased in the majority of patients with a median of 80% JAK2 V617F/HCK (range 0.2-100%) before HCT (Figure 1) .
Excluding the three patients who discontinued ruxolitinib and received IC because of LT or progressive leukocytosis, ruxolitinib was tapered and continued up to the day preceding the start of the conditioning regimen to minimize the risk of potential withdrawal symptoms during ruxolitinib treatment discontinuation. 12 Tapering depended on the dose a patient was receiving 2 weeks before the start of conditioning. Generally, the maximal ruxolitinib dose was adjusted to 10 mg BID for 7 days followed by 5 mg BID, which was continued for the succeeding 7 days including the day which preceded conditioning.
Outcome after allogeneic HCT The type of conditioning depended on age and previous treatments. Myeloablative conditioning was offered to three patients X50 years of age (patient nos. 9, 13, 14) .
To minimize the toxicity of conditioning, fludarabine-based RIC in combination with 2 Gy TBI was given to the three patients who were treated with IC after ruxolitinib (patient nos. 2, 5, 12) and to patient no. 10 who has received a futile IC because of massive splenomegaly and debilitating constitutional symptoms before ruxolitinib. In the remaining seven patients (50%), conditioning consisted of fludarabine-based RIC in combination with 8 mg/kg BU p.o given over 2 days.
No significant withdrawal symptoms were noted, and conditioning was generally well tolerated without unexpected adverse events. Engraftment after allogeneic HCT, defined as the first of 3 consecutive days with leukocyte count41.0 Â 10 9 /L, occurred in 13 (93%) patients after a median of 20 (range 9-51) days. Median donor chimerism in unsorted mononuclear and CD3 þ cells in the BM on day 28 after allogeneic HCT were 96% and 85%, respectively.
Acute GvHD occurred in 6 (43%) patients (pgrade II in 4 (28.6%) and grade III in 2 (14%) patients). After a median follow-up of 9 (range 4-34) months after allogeneic HCT, 11 (78.6%) patients were alive and 9 (64%) patients event free. TRM was 7%. The overall probability of survival at 1 year was 50% (Figure 2) . Nine of the 11 (69%) patients who were transplanted directly after ruxolitinib survived (Table 3) . Excluding the two patients with engraftment failure and early relapse of AML after allogeneic HCT, the allele burden in patients with JAK2V617F-positive disease decreased rapidly with 5/7 (71%) patients havingo1% JAK2 V617F-mutated allele at day 28 (Figure 1 ). To date, TRM due to sepsis occurred in one patient (7%) after 10 months. Secondary AML after allogeneic HCT was diagnosed in two patients who received IC before transplantation due to LT or rapidly progressive leucocytosis under ruxolitinib.
Of particular interest is patient no. 11 who died 9.5 months after allogeneic HCT because of progressive marrow fibrosis with massive splenomegaly despite a 100% donor chimerism. Surprisingly, the JAK2V617F mutation was identified after transplantation for the first time although several evaluations confirmed the absence of the mutation before allogeneic HCT (Figure 3) . Reevaluation of the otherwise completely healthy MRD (brother) confirmed the presence of the JAK2V617F mutation without clinical features of a myeloproliferative neoplasia (MPN).
DISCUSSION
To our knowledge, these are the first data on the use of ruxolitinib before allogeneic HCT in patients with MF. Although sample size is small and follow-up short, several observations can be made concerning patient selection, timing and outcome of allogeneic HCT in the era of ruxolitinib.
The IPSS, DIPSS, DIPSS plus and the Lille scoring systems are used for risk stratification regarding survival and decision making in patients with MF. Although not validated in patients with post-PV-and post ET-MF, these scoring systems are also used in these entities. Transplantation is usually considered for patients with intermediate-2 or high risk MF. 1, 13 Before commencing ruxolitinib, analysis of the prognostic factors relevant for survival revealed that 12 (85%) patients were at high risk and intermediate-2 risk according to IPPS. Two of the three patients with low risk according to the Lille score had intermediate- Response occurred at week 4 and was lost at the time of leukemic transformation (LT) 4 weeks later.
c Response occurred at week 8 with a duration of 4 months and was lost at the time of LT. d Response occurred at week 8 but progressive leucocytosis with 5% blasts in the peripheral blood emerged at week 10. 2 risk according to the IPSS. On the other hand, one patient with intermediate-1 risk had an unexpected early LT. This displays the dilemma of allocating the 'right' patient to allogeneic HCT. To avoid inappropriately delaying allogeneic HCT in candidate patients with high risk disease, prognostically relevant parameters, including cytogenetics, need to be periodically evaluated. The complex risk stratification for patient allocation to HCT might be further complicated by ruxolitinib-related hematological adverse events, which need to be differentiated from MF-related changes. For example, the acquisition of anemia has a higher adverse impact on survival compared with other factors in the DIPSS; therefore, anemia was assigned a score of 2.
6 Platelet count has also been incorporated into the DIPSS plus as a prognostic relevant factor. 7 In the ruxolitinib era, physicians might be faced with an extra challenge of segregating anemia and thrombocytopenia caused by ruxolitinib from those due to MF as occurred in two of our patients. Under ruxolitinib, thrombocytopenia and anemia are generally observed within the first months after initiating therapy, manageable with dose modifications and reach a steady state by week 24.
2,3 Thus, late changes in hemoglobin and platelet values emerging under a constant dose of ruxolitinib might indicate worsening of MF rather than being an adverse event of therapy and need to be carefully evaluated.
Certain patient-, disease-and transplant-related parameters are used to predict outcome after allogeneic HCT for MF. Age, PS and splenomegaly have all been identified as patient-related predictive factors. Age 455 years is identified as an independent prognostic factor for mortality after allogeneic HCT. 14, 15 Ten ( 64%) patients in this study were 455 years.
Both massive splenomegaly and MF-related symptoms contribute largely to the disease burden in patients with MF, restrict physical activity and reduce PS. Also, poor PS and splenomegaly 422 cm at allogeneic HCT have also been associated with poor survival. 16, 17 Although the spleen can easily be measured, the impact of MF-related symptoms on PS is more difficult to quantify. In clinical trials, comprehensive quality-of-life assessments were incorporated to evaluate response to treatment with ruxolitinib. 2, 3 In daily practice, such tools are often not available, and judgment is largely subjective. For assessment of response to guide decision making regarding timing of allogeneic HCT, we used an abbreviated self-reporting questionnaire including the major contributors to poor quality of life in patients with MF (constitutional symptoms according to the IPSS (weight loss, unexplained fever, and night sweats) as well as fatigue, bone pain and pruritus). This enabled an objective and simple measurement of disease-related symptoms and response to ruxolitinib before allogeneic HCT. Whether the depth and rapidity of a response to ruxolitinib could be translated into a 'predictor' for transplant outcome is an interesting issue, which could not be answered at the present time.
Tapering and continuing ruxolitinib until conditioning in our patients might explain the paucity of relevant withdrawal symptoms or explosive splenomegaly due to cytokine excess. Nevertheless, this schedule needs further validation.
Engraftment after allogeneic HCT occurred in 93% of patients. One graft failure occurred in the group of 11 patients who received a transplant from a MUD. The rather high incidence of graft failure observed in MF patients, particularly following MUD (up to 20%), has been attributed, at least in part, to the high cytokines in these patients. 16, 18 Further, there were no particular concerns regarding hematological recovery in our cohort. It is well appreciated that hematopoietic recovery is faster in splenectomized patients. [19] [20] [21] Thus, pretreatment with ruxolitinib might actually facilitate both engraftment and hematological recovery after allogeneic HCT through the reduction in cytokine levels and splenomegaly.
MF patients might be exposed to a higher risk of GvHD due to increased inflammatory cytokines. 22 There seemed to be no increased risk of acute GvHD in our study population, although the number is too small to draw firm conclusions. Evidence exists that the risk scores used to estimate survival in patients with MF (DIPSS, DIPSS plus and Lille) might also predict outcome after allogeneic HCT. Intermedite-2 and high-risk patients have a higher risk of relapse and TRM, as well as an inferior survival compared with low-risk patients. 14, 23 On the whole, published results on outcome after allogeneic HCT indicate that TRM at 1 year is 10-48%, and PFS at 3 years is 40-50%. 13 Although follow-up is short, short-term results of transplantation following ruxolitinib in our cohort comprising patients with negative patient-and disease-predictive factors for outcome after allogeneic HCT were at least comparable to the published series. Moreover, excluding the two patients with engraftment failure and early relapse of AML after allogeneic HCT, the allele burden in patients with JAK2V617F-positive disease decreased rapidly with 71% of patients having o1% JAK2 V617F-mutated allele at day 28, which is known to correlate with a good outcome and low relapse risk. 10 Longer follow-up in larger series is required to answer the question of whether ruxolitinib treatment could partly abrogate the negative prognostic impact of high-risk MF on outcome after allogeneic HCT.
One matter related to the patient with progressive marrow fibrosis despite a 100% donor chimerism needs to be mentioned. The JAK2V617F mutation was identified after allogeneic HCT although several evaluations confirmed the absence of this mutation before transplantation (Figure 3 ). Re-evaluation of the otherwise completely healthy MRD (brother) confirmed the presence of the JAK2V617F mutation without clinical features of MPN. It is known that there is an increased incidence of MPN among first-degree relatives with a relative risk of 5.5-7.6%. 24 It is suggested that the 'familial MPN susceptibility gene' might exist in a multipotent stem cell and that the familial clustering of MPN is associated with a genetic heterogeneity, multifactorial inheritance or autosomal dominant inheritance with variable penetrance. 25 In conclusion, treatment with the JAK1 and JAK2 inhibitor ruxolitinib and allogeneic HCT are not mutually exclusive. Through the reduction of proinflammatory and proangiogenic cytokines, some of the patient-related negative predictors for outcome after allogeneic HCT such as poor PS and massive splenomegaly might be, at least partly, counteracted. Further, the rapid downregulation of inflammatory cytokines might have a beneficial impact on graft failure and acute GvHD. On the other hand, some caveats to the use of ruxolitinib in the setting of allogeneic HCT must be remembered such as the differentiation between ruxolitinibrelated hematological adverse events and progression of MF, which might cause an inappropriate delay in allogeneic HCT. Further follow-up and larger number of patients are needed to validate the observations made and to establish the exact role of ruxolitinib in the transplant setting.
